An assessment of regional versus systemic thrombolytic treatment of peripheral and coronary artery thrombosis.
D000925:Anticoagulants / Q000627:therapeutic use; D002404:Catheterization; D003327:Coronary Disease / Q000188:drug therapy*; D004341:Drug Evaluation; D005337:Fibrin / Q000378:metabolism; D005341:Fibrinolysin / Q000502:physiology; D005342:Fibrinolysis; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007261:Infusions, Intra-Arterial; D007263:Infusions, Parenteral; D009203:Myocardial Infarction / Q000188:drug therapy; D010958:Plasminogen / Q000502:physiology; D010960:Plasminogen Activators / Q000502:physiology / Q000627:therapeutic use; D013300:Streptokinase / Q000627:therapeutic use; D013927:Thrombosis / Q000188:drug therapy*; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use; D000979:alpha-2-Antiplasmin / Q000502:physiology
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D000979:alpha-2-Antiplasmin; D005337:Fibrin; D010958:Plasminogen; D013300:Streptokinase; D010960:Plasminogen Activators; D005341:Fibrinolysin; D014568:Urokinase-Type Plasminogen Activator